JF
LTRN icon

Jump Financial’s Lantern Pharma LTRN Stock Holding History

Jump Financial’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,900
Closed -$60.2K – 1918
2024
Q2 		$60.2K Buy
+12,900
New +$77.6K ﹤0.01% 1680
2022
Q1 		– Sell
-11,028
Closed -$88K – 1741
2021
Q4 		$88K Buy
+11,028
New +$101K 0.01% 1238

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jump Financial's LTRN Position: Q3 2024 in Review

Jump Financial sold out of Lantern Pharma (LTRN) in Q3 2024, closing a stake of 12,900 shares — an estimated $60.2K sold.

Jump Financial first reported a position in LTRN in Q4 2021 and held it in 2 quarters. The position peaked at $88K in Q4 2021. 31 funds tracked by Wall St. Rank hold LTRN as of Q3 2024.

  • Jump Financial reported no remaining Lantern Pharma position as of Q3 2024 after selling out during the quarter.
  • Jump Financial sold 12,900 Lantern Pharma shares in Q3 2024, an estimated $60.2K.
  • Jump Financial first reported a position in Lantern Pharma in Q4 2021 and held it in 2 quarters.
  • Jump Financial's Lantern Pharma position peaked at $88K in Q4 2021.
  • 31 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2024.

Based on Jump Financial's 13F filing for Q3 2024, filed 14 Nov 2024.